We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.5B
AUM Growth
+$439M
Cap. Flow
+$1.2M
Cap. Flow %
0.02%
Top 10 Hldgs %
41.65%
Holding
136
New
22
Increased
21
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$87.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$46.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.6M
4
AMGN icon
Amgen
AMGN
+$38.4M
5
UNH icon
UnitedHealth
UNH
+$37.9M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$74.9M
2
THC icon
Tenet Healthcare
THC
+$59.2M
3
VRNA
Verona Pharma
VRNA
+$41.4M
4
GERN icon
Geron
GERN
+$40.6M
5
PCVX icon
Vaxcyte
PCVX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
1
Edgewise Therapeutics
EWTX
$4.34B
$401M 7.29%
15,021,721
– –
SVA
2
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.18%
2,718,735
– –
LLY icon
3
Eli Lilly
LLY
$1.09T
$299M 5.43%
337,600
– –
BSX icon
4
Boston Scientific
BSX
$68.5B
$274M 4.98%
3,273,000
– –
ISRG icon
5
Intuitive Surgical
ISRG
$130B
$213M 3.87%
433,800
-59,300
-12% -$27.6M
ELVN icon
6
Enliven Therapeutics
ELVN
$3.84B
$203M 3.69%
7,959,538
– –
BIIB icon
7
Biogen
BIIB
$30.4B
$158M 2.86%
813,000
-87,900
-10% -$18.4M
MRK icon
8
Merck
MRK
$326B
$149M 2.72%
1,316,000
– –
THC icon
9
Tenet Healthcare
THC
$22.6B
$130M 2.36%
782,000
-391,300
-33% -$59.2M
SYK icon
10
Stryker
SYK
$133B
$124M 2.26%
344,400
+75,400
+28% +$26M
SPRY icon
11
ARS Pharmaceuticals
SPRY
$563M
$120M 2.18%
8,288,510
-952,377
-10% -$11.3M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.63B
$119M 2.17%
954,500
+308,500
+48% +$42.6M
ARGX icon
13
argenx
ARGX
$54.6B
$111M 2.01%
204,500
-4,600
-2% -$2.32M
UNH icon
14
UnitedHealth
UNH
$389B
$105M 1.9%
179,000
+67,000
+60% +$37.9M
QTTB icon
15
Q32 Bio
QTTB
$467M
$101M 1.83%
2,252,987
– –
MBX
16
MBX Biosciences
MBX
$2.86B
$99M 1.8%
+3,812,215
New +$87.2M
IONS icon
17
Ionis Pharmaceuticals
IONS
$9.14B
$93.1M 1.69%
2,324,447
-47,886
-2% -$2.23M
IRON icon
18
Disc Medicine
IRON
$2.85B
$87.7M 1.59%
1,785,571
– –
NTRA icon
19
Natera
NTRA
$36.1B
$87.3M 1.59%
687,500
– –
AMGN icon
20
Amgen
AMGN
$212B
$81.3M 1.48%
252,300
+117,400
+87% +$38.4M
THRD
21
DELISTED
Third Harmonic Bio
THRD
$78.3M 1.42%
5,779,071
– –
ITGR icon
22
Integer Holdings
ITGR
$3.41B
$74.8M 1.36%
575,000
+225,779
+65% +$27.6M
AVBP icon
23
ArriVent BioPharma
AVBP
$1.4B
$71.1M 1.29%
3,027,328
– –
VRTX icon
24
Vertex Pharmaceuticals
VRTX
$124B
$70.2M 1.28%
151,000
– –
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$38.5B
$68.8M 1.25%
250,300
– –
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2024 Portfolio in Review

As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

  • OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
  • OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
  • OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
  • OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q3 2024.
  • OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.